Idactamab INT-001 represents an exciting therapeutic method for managing specific hematologic tumors. This particular immunoglobulin is the unique mechanism of action, particularly binding to CD38, an cell-surface https://mediajx.com/story27754013/idacta-mab-int-001-a-novel-immunoglobulin-during-progression